BioCentury | Jun 4, 2020
Finance

Everest to fund late-stage trials with $310M mountain of fresh cash

...for ulcerative colitis, the rights to which Everest has obtained from Arena Pharmaceuticals Inc. (NASDAQ:ARNA); PGI2...
...FGFR4 (CD334) - Fibroblast growth factor receptor 4 LACTB - Beta lactamase PGI2 (PTGIR) - Prostacyclin receptor...
BioCentury | Sep 23, 2019
Clinical News

Cerevel set for Phase III as tavapadon meets in early Parkinson’s

Eleven months after Bain Capital and Pfizer formed Cerevel to house the pharma’s discontinued neuroscience pipeline, the biotech is sending its Parkinson’s disease program to Phase III on the strength of its Phase II readout...
BioCentury | Nov 30, 2018
Targets & Mechanisms

Revving up metabolism at ASH 2018

...2 facilitated glucose transporter member 1 (SLC2A; GLUT1) 4 Glucose-6-phosphate dehydrogenase (G6PD) 8 Prostacyclin receptor (PGI2; PTGIR...
BioCentury | Nov 16, 2018
Company News

Arena licenses ralinepag to United, moves S1PR1 agonist to center stage

...2021. The prostacyclin receptor (PGI2; PTGIR) agonist eventually could compete with Uptravi selexipag, the sole marketed PGI2...
...etrasimod in the territories. Jennie Walters etrasimod (APD334) olorinab (APD371) ralinepag (APD811) Arena Pharmaceuticals Inc. United Therapeutics Corp. Cannabinoid receptor 2 (CB2) (CNR2) Prostacyclin (IP) receptor (PGI2) (PTGIR) Sphingosine...
BioCentury | Nov 16, 2018
Company News

Arena licenses ralinepag to United, moves S1PR1 agonist to center stage

...2021. The prostacyclin receptor (PGI2; PTGIR) agonist eventually could compete with Uptravi selexipag, the sole marketed PGI2...
...Business: Cardiovascular Jennie Walters etrasimod (APD334) olorinab (APD371) ralinepag (APD811) Arena Pharmaceuticals Inc. Johnson & Johnson United Therapeutics Corp. Cannabinoid receptor 2 (CB2) (CNR2) Prostacyclin (IP) receptor (PGI2) (PTGIR) Sphingosine...
BioCentury | Jun 22, 2018
Clinical News

ObsEva's linzagolix meets in Phase IIb for endometriosis-associated pain

ObsEva S.A. (NASDAQ:OBSV) said three of four doses of linzagolix (OBE2109, KLH-2109) met the primary endpoint in the Phase IIb EDELWEISS trial to treat moderate to severe endometriosis-associated pain. The company plans to present additional...
BioCentury | May 18, 2018
Clinical News

Lilly reports mixed data for CGRP mAb in Phase III cluster headache trials

Eli Lilly and Co. (NYSE:LLY) said galcanezumab met the primary endpoint in a Phase III trial to prevent episodic cluster headache but missed in a Phase III trial in chronic cluster headache. Lilly said it...
BioCentury | Mar 9, 2018
Clinical News

GTx reports additional Phase II stress urinary incontinence data for enobosarm

GTx Inc. (NASDAQ:GTXI) reported data from 18 postmenopausal women with stress urinary incontinence in a Phase II proof-of-concept trial of enobosarm (GTx-024). The candidate is a non-steroidal selective androgen receptor modulator (SARM). On the primary...
BioCentury | Feb 23, 2018
Company News

Everest gets rights to Tetraphase antibiotic

...Taiwan, Hong Kong, Macau and South Korea. Ralinepag is an oral agonist of prostacyclin (IP) receptor (PGI2; PTGIR...
...Mass. Everest Medicines Ltd., Boston, Mass. Business: Infectious Elizabeth S. Eaton etrasimod ralinepag Arena Pharmaceuticals Inc. Everest Medicines Ltd. Tetraphase Pharmaceuticals Inc. Prostacyclin (IP) receptor (PGI2) (PTGIR) Sphingosine...
BioCentury | Feb 20, 2018
Company News

Everest gets rights to Tetraphase antibiotic

...Taiwan, Hong Kong, Macau and South Korea. Ralinepag is an oral agonist of prostacyclin (IP) receptor (PGI2; PTGIR...
...Tuesday; the deal was announced after market close. Elizabeth S. Eaton etrasimod ralinepag TP-434 Arena Pharmaceuticals Inc. Everest Medicines Ltd. Tetraphase Pharmaceuticals Inc. Prostacyclin (IP) receptor (PGI2) (PTGIR) Sphingosine...
Items per page:
1 - 10 of 137